BDSI expects $50 million in latest public offering
April 11, 2019 at 10:45 AM EDT
Following the announcement of the $30 million acquisition of U.S. commercialization rights to a Japanese drug, Raleigh's BDSI has priced its public offering – anticipating gross proceeds of $50 million.
